Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation
- PMID: 21609205
- DOI: 10.3109/14653249.2011.579956
Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation
Abstract
Background aims: Granulocyte-macrophage (GM) colony-stimulating factor (CSF) has been used as an adjuvant in cancer immunotherapy. We tested the hypothesis that GM-CSF (Leukine(®); sargramostim) improves immune reconstitution after hematopoietic stem cell transplantation (HSCT) based on our prior in vitro work that demonstrated the pro-inflammatory effects of GM-CSF on dendritic cells (DC).
Methods: GM-CSF was administered to donors, along with standard granulocyte (G) CSF, during stem cell mobilization, and to recipients from the day prior to transplant until engraftment. Eighteen patients consented to the GM-CSF(+) protocol and were compared with 17 matched controls undergoing HSCT during the same time period (GM-CSF(-)).
Results: Numbers of white blood cells (WBC) and CD34(+) stem cells in the graft were comparable to controls. Surprisingly, contrary to our hypothesis, the allogeneic donor graft had significantly decreased numbers of CD3(+) T cells and their subsets (CD4(+), CD4(+) CD45RA(+), CD4(+) CD45RO(+), CD8(+) and CD8(+) CD45RO(+)), DC (both myeloid and plasmacytoid) and natural killer (NK) cells (CD16(+) CD56(+)). In the GM-CSF arm, following allogeneic transplantation, the levels of DC, T cells and NK cells did not increase with treatment. Conversely, autologous transplant patients receiving GM-CSF had a higher proportion of DC at the time of engraftment.
Conclusions: These findings demonstrate that administration of GM-CSF improves DC reconstitution after autologous rather than allogeneic HSCT.
Similar articles
-
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.Biol Blood Marrow Transplant. 2013 Mar;19(3):460-7. doi: 10.1016/j.bbmt.2012.11.017. Epub 2012 Nov 28. Biol Blood Marrow Transplant. 2013. PMID: 23201472 Clinical Trial.
-
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.Biol Blood Marrow Transplant. 2004 Dec;10(12):848-57. doi: 10.1016/j.bbmt.2004.07.008. Biol Blood Marrow Transplant. 2004. PMID: 15570253 Clinical Trial.
-
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10. Transfusion. 2011. PMID: 21392017
-
Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells.Curr Opin Hematol. 2002 May;9(3):190-8. doi: 10.1097/00062752-200205000-00003. Curr Opin Hematol. 2002. PMID: 11953663 Review.
-
Granulocyte-macrophage colony-stimulating factor and the immune system.Med Oncol. 1996 Sep;13(3):133-40. doi: 10.1007/BF02990841. Med Oncol. 1996. PMID: 9106171 Review.
Cited by
-
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.Cancer Immunol Res. 2015 Apr;3(4):320-5. doi: 10.1158/2326-6066.CIR-14-0100. Epub 2014 Nov 11. Cancer Immunol Res. 2015. PMID: 25387895 Free PMC article.
-
Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC.Int J Mol Sci. 2021 Jan 27;22(3):1241. doi: 10.3390/ijms22031241. Int J Mol Sci. 2021. PMID: 33513928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials